Australian medical practitioners are prescribing medicinal cannabis products containing delta-9-tetrahydrocannabinol (THC) concentrations up to four times higher than those evaluated in clinical trials. A Monash University review reveals that despite over 1,000 products being available, only two have been evaluated by the drug regulator.
In Plain English: The Clinical Takeaway
- Regulatory Oversight: Out of more than 1,000 medicinal cannabis items on the market, only two have been evaluated by the drug regulator.
Evaluating the Evidence: Monash University Findings and Clinical Realities
Researchers at Monash University evaluated the available evidence for the efficacy and safety of higher THC potency medicinal cannabis products, in line with those being prescribed in Australia. Delta-9-tetrahydrocannabinol is the main psychoactive ingredient of cannabis.
| Metric | Clinical Trial Standard | Commercial Prescription Reality |
|---|---|---|
| THC Concentration | Standardized doses | Up to 4x higher than trial benchmarks |
| Regulator Evaluation | Clinical review | Only two products evaluated |
| Product Variety | Controlled batches | Over 1,000 distinct products available |
Global Regulatory Context and Patient Access
Contraindications & When to Consult a Doctor
The Path Forward for Evidence-Based Prescribing
References
- Monash University. Review of medicinal cannabis efficacy and safety.
Disclaimer: This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition.
